Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 13/20 | 0.39 |
| ▸ | MMP9 | P14780 | 13/20 | 0.39 |
| ▸ | MMP3 | P08254 | 10/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998815 | 0.92 | MMP1 (0.41) | MEN1KMT2ALMNAHPGDMMP1 | |
| SCHEMBL5997643 | 0.92 | LMNA (0.40) | MEN1KMT2ALMNAHPGDMAPT | |
| SCHEMBL5998656 | 0.87 | ALDH1A1 (0.42) | MEN1KMT2ALMNAHPGDMMP1 | |
| SCHEMBL5998825 | 0.84 | MEN1 (0.39) | MEN1KMT2ALMNAHPGDMMP1 | |
| SCHEMBL5997176 | 0.82 | TSHR (0.39) | MEN1KMT2ALMNAHPGDMAPT | |
| SCHEMBL5998320 | 0.79 | MMP1 (0.38) | LMNAHPGDMMP1MMP9MMP3 | |
| SCHEMBL5998414 | 0.78 | MEN1 (0.43) | MEN1KMT2ALMNAHPGDMAPT | |
| SCHEMBL5997292 | 0.78 | ALDH1A1 (0.43) | MEN1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL5997628 | 0.78 | ALDH1A1 (0.34) | MEN1KMT2ALMNAHPGDMAPT | |
| SCHEMBL5996133 | 0.77 | DRD2 (0.40) | MEN1KMT2ALMNAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094908-B2 | Reduction of carbonyl compounds using the carbonyl reductase of Kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2006-08-22 | — | — | US | disclosed |
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | CBR1, CBR3, DCXR | MEN1 3483/4885KMT2A 1280/4885LMNA 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.